Tower Research Capital LLC TRC raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 368.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,580 shares of the company's stock after purchasing an additional 8,323 shares during the period. Tower Research Capital LLC TRC's holdings in Neurocrine Biosciences were worth $1,444,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Neurocrine Biosciences by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company's stock valued at $1,381,331,000 after purchasing an additional 122,681 shares during the period. Dodge & Cox increased its stake in shares of Neurocrine Biosciences by 134.2% in the fourth quarter. Dodge & Cox now owns 3,016,425 shares of the company's stock worth $411,742,000 after purchasing an additional 1,728,605 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Neurocrine Biosciences by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company's stock valued at $255,523,000 after purchasing an additional 15,830 shares during the period. Wellington Management Group LLP boosted its stake in shares of Neurocrine Biosciences by 102.9% in the fourth quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company's stock worth $198,939,000 after acquiring an additional 739,199 shares during the period. Finally, Invesco Ltd. grew its stake in Neurocrine Biosciences by 8.6% during the fourth quarter. Invesco Ltd. now owns 949,512 shares of the company's stock valued at $129,608,000 after acquiring an additional 74,847 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.
Insider Buying and Selling
In other Neurocrine Biosciences news, insider Julie Cooke sold 1,740 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $152.89, for a total transaction of $266,028.60. Following the completion of the transaction, the insider now owns 18,202 shares in the company, valued at approximately $2,782,903.78. This represents a 8.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kevin Charles Gorman sold 2,707 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $152.92, for a total value of $413,954.44. Following the transaction, the director now owns 517,030 shares of the company's stock, valued at approximately $79,064,227.60. The trade was a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,801 shares of company stock worth $2,834,677 in the last 90 days. 4.30% of the stock is owned by company insiders.
Neurocrine Biosciences Trading Up 1.9 %
Neurocrine Biosciences stock traded up $2.05 during mid-day trading on Tuesday, hitting $108.51. 132,074 shares of the company's stock were exchanged, compared to its average volume of 1,064,460. The stock has a market cap of $10.74 billion, a P/E ratio of 33.00, a P/E/G ratio of 0.77 and a beta of 0.33. The stock has a 50 day moving average of $107.00 and a two-hundred day moving average of $122.16. Neurocrine Biosciences, Inc. has a 1-year low of $84.23 and a 1-year high of $157.98.
Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. As a group, research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.
Neurocrine Biosciences announced that its board has initiated a share repurchase plan on Friday, February 21st that authorizes the company to repurchase $500.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 4.2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its shares are undervalued.
Wall Street Analyst Weigh In
Several research analysts recently commented on the company. Guggenheim dropped their price target on Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating for the company in a research report on Monday, February 10th. StockNews.com lowered shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th. Evercore ISI cut their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. UBS Group decreased their target price on Neurocrine Biosciences from $154.00 to $137.00 and set a "buy" rating on the stock in a research report on Friday, April 4th. Finally, JPMorgan Chase & Co. raised their price target on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 26th. Three equities research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $160.90.
Check Out Our Latest Stock Analysis on Neurocrine Biosciences
Neurocrine Biosciences Company Profile
(
Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Featured Stories
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
